Skip to content

   Pharma Publications

Neuropsychopharmacology
  • Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective
    Published on 2024-08-21
    2 years ago
  • A new prism next to motherhood’s light: uncovering changes in neural function following childbirth
    Published on 2024-08-20
    2 years ago
  • Neuromelanin-sensitive MRI for mechanistic research and biomarker development in psychiatry
    Published on 2024-08-19
    2 years ago
  • Basal forebrain-lateral habenula inputs and control of impulsive behavior
    Published on 2024-08-18
    2 years ago
  • Concurrent and longitudinal neurostructural correlates of irritability in children
    Published on 2024-08-17
    2 years ago
  • Distributed circuits regulating defensive state transitions: freezing, flight and fight
    Published on 2024-08-16
    2 years ago
  • AMPA receptors modulate enhanced dopamine neuronal activity induced by the combined administration of venlafaxine and brexpiprazole
    Published on 2024-08-15
    2 years ago
« Previous 1 … 68 69 70 71 72 … 143 Next »
Journal of Psychopharmacology
  • Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes
    Published on 2022-10-31
    4 years ago
  • The influence of stimulus onset asynchrony, task order, sex and hormonal contraception on prepulse inhibition and prepulse facilitation: Methodological considerations for drug and imaging research
    Published on 2022-10-21
    4 years ago
  • Clinical correlates of early onset antipsychotic treatment resistance
    Published on 2022-10-21
    4 years ago
  • Validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview among outpatients with schizophrenia
    Published on 2022-10-21
    4 years ago
  • Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy—A systematized review
    Published on 2022-10-20
    4 years ago
  • D2-like receptor activation by intranasal dopamine attenuates fear responses induced by electrical stimulation of the dorsal periaqueductal grey matter, but fails to reduce aversion to pit vipers and T-maze performance
    Published on 2022-10-14
    4 years ago
  • Efficacy of aripiprazole as adjunctive therapy in major depressive disorder with somatic symptoms: A randomized, double-blind, placebo-controlled trial with clinical and electroencephalography evidence
    Published on 2022-10-14
    4 years ago
« Previous 1 … 68 69 70 71 72 … 145 Next »
European Neuropsychopharmacology
  • Treating major depressive disorder with mixed features
    Published on 2023-02-13
    3 years ago
  • New biomarkers in mood disorders: Insights from immunopsychiatry and neuroimaging
    Published on 2023-02-13
    3 years ago
  • In vivo serotonin transporter and 1A receptor binding potential and ecological momentary assessment (EMA) of stress in major depression and suicidal behavior
    Published on 2023-02-12
    3 years ago
  • Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes
    Published on 2023-02-08
    3 years ago
  • Initial response to the COVID-19 pandemic on real-life well-being, social contact and roaming behavior in patients with schizophrenia, major depression and healthy controls: A longitudinal ecological momentary assessment study
    Published on 2023-02-03
    3 years ago
  • Higher lymphocyte count associated with larger hippocampal volume and fewer depressive symptoms in drug–na ïve first-episode psychosis
    Published on 2023-01-28
    3 years ago
  • Number needed to treat and number needed to harm: What are they good for?
    Published on 2023-01-27
    3 years ago
« Previous 1 … 68 69 70 71 72 … 166 Next »

   Pharma Pub